Pollard M
Lobund Laboratory, University of Notre Dame, Indiana 46556, USA.
Prostate. 1999 Jun 1;39(4):305-9. doi: 10.1002/(sici)1097-0045(19990601)39:4<305::aid-pros12>3.0.co;2-y.
Since prostate cancer (PC) development involves a combination of genetic predisposition and promotional mechanisms, especially the metabolic conversion of testosterone to 5alpha dihydrotestosterone (DHT) by 5alpha reductase, how do mechanisms in man relate to prostate-seminal vesicle (P-SV) tumor development in Lobund-Wistar (L-W) rats? The disease in man and in L-W rats shares developmental mechanisms and characteristics to the extent that prevention of P-SV tumors in L-W rats could be predictive of similar results in man. The epidemiology of PC in man and P-SV tumors in L-W rats indicates that both are hormone-related diseases based on genetic predisposition, high production of androgens (which are activated to DHT by 5alpha reductase), and early development of androgen-dependent and metastasizing late androgen-independent stages of adenocarcinomas, all after long latency periods.
L-W rats at risk of developing spontaneous or induced P-SV tumors were subjected to putative antitumor agents or procedures. These included dietary restriction, testosterone ablation, soybean-derived isoflavones, antiangiogenic linomide, tamoxifen, and a vitamin D analogue.
L-W rats subjected to 1) early onset of dietary restriction manifested suppression of spontaneous and induced development of P-SV tumors; 2) testosterone-ablation by nonesterified DHT (NE-DHT) suppressed early onset of induced P-SV tumors and to a lesser extent late onset of spontaneous tumors; 3) diets containing soy protein isolate (high isoflavones) manifested marginal suppressive effects against induced P-SV tumors, but in 12-month-old rats, the development of spontaneous tumors was reduced in incidence; 4) early administrations of antiangiogenic linomide suppressed development of induced P-SV tumors and of transplanted prostate adenocarcinoma III (PA-III) tumors, but linomide had little antitumor effect against large advanced stage tumors; and 5) tamoxifen and vitamin D analogue suppressed development of P-SV tumors. Results in conditions 1-3 were negative when tested against PA-III tumors.
Developing stages of P-SV tumors were prevented in L-W rats with autochthonous spontaneous and induced tumors, but most of the agents tested were of no therapeutic benefit against advanced-stage and transplanted PA-III tumors. However, early administrations of antiangiogenic linomide suppressed early growth of induced and transplanted PA-III tumors.
由于前列腺癌(PC)的发生涉及遗传易感性和促进机制的共同作用,尤其是5α还原酶将睾酮代谢转化为5α二氢睾酮(DHT)的过程,那么人类中的这些机制与Lobund-Wistar(L-W)大鼠的前列腺-精囊(P-SV)肿瘤发生有何关联呢?人类和L-W大鼠的这种疾病在发育机制和特征上有一定共性,以至于预防L-W大鼠的P-SV肿瘤可能预示着人类也会有类似结果。人类PC和L-W大鼠P-SV肿瘤的流行病学表明,两者都是基于遗传易感性、雄激素高分泌(经5α还原酶激活为DHT)以及腺癌雄激素依赖早期阶段和晚期雄激素非依赖转移阶段的早期发展的激素相关疾病,且都有较长的潜伏期。
将有发生自发性或诱发性P-SV肿瘤风险的L-W大鼠给予假定的抗肿瘤药物或进行相关操作。这些包括饮食限制、睾酮去除、大豆来源的异黄酮、抗血管生成药物利诺胺、他莫昔芬和一种维生素D类似物。
对L-W大鼠进行以下处理后,结果如下:1)早期开始饮食限制可抑制P-SV肿瘤的自发性和诱发性发展;2)用非酯化DHT(NE-DHT)去除睾酮可抑制诱发性P-SV肿瘤的早期发生,并在较小程度上抑制自发性肿瘤的晚期发生;3)含有大豆分离蛋白(高异黄酮)的饮食对诱发性P-SV肿瘤有轻微抑制作用,但在12月龄大鼠中,自发性肿瘤的发生率有所降低;4)早期给予抗血管生成药物利诺胺可抑制诱发性P-SV肿瘤和移植性前列腺腺癌III(PA-III)肿瘤的发展,但利诺胺对大型晚期肿瘤几乎没有抗肿瘤作用;5)他莫昔芬和维生素D类似物可抑制P-SV肿瘤的发展。在针对PA-III肿瘤进行测试时,上述1-3种情况的结果为阴性。
L-W大鼠自身发生自发性和诱发性肿瘤时,其P-SV肿瘤的发展阶段得到了预防,但大多数测试药物对晚期和移植性PA-III肿瘤并无治疗益处。然而,早期给予抗血管生成药物利诺胺可抑制诱发性和移植性PA-III肿瘤的早期生长。